Table 1 In vitro generation of immortalized red blood cell line using human papillomavirus oncogenes
References | Vector/plasmid/other systems for immortalization | Genes used for immortalization | Inducible | Cell origin | Cells used | Proliferation time | Hemoglobin production | Percent of enucleation (%) |
|---|---|---|---|---|---|---|---|---|
Akimov et al. [62] | Lentiviral vector | hTERT and/or HPV16 E6/E7 | No | UCB | CD34+ |  ~ 24 months | – | – |
Wong et al. 2010 | Lentiviral vector | SV40T, hTERT, or HPV16 E6/E7 | No | PB | CD36+ |  > 1 month | γ- > β-globin | – |
Kurita et al. [59] | Lentiviral vector | HPV16 E6/E7 | Tet-inducible | UCB | iPS cell lines and CD34+ |  > 12 months | β- or γ-globin | N.R |
Trakarnsanga et al. [60] | Lentiviral vector | HPV16 E6/E7 | Tet-inducible | BM | CD34+ |  > 6 months |  ~ 99% β-globin | 30 |
Kurita et al. [61] | Lentiviral vector | HPV16 E6/E7 | Tet-inducible | BM | CD34+ and CD34+ | from 1 to 8 months |  ~ 96% β-globin  ~ 2% γ-globin |  ~ 25 |
Trakarnsanga et al. [69] | Lentiviral vector | HPV16 E6/E7 | Tet-inducible | β-thalassemic PB patient | CD34+ |  > 3 months | 29.2% of HbF 9.0% of HbA 61.8% of HbE |  ~ 10 |
Daniels et al. [16] | Lentiviral vector | HPV16 E6/E7 | Tet-inducible | BM, PB, UCB | CD34+ |  > 6 months | BEL-C: γ > β BEL-P: β- > γ-globin |  ~ 26 |
Bagchi et al. [76] | Lentiviral vector | HPV16 E6/E7 | No | PB BM | PB-EPCs CD34+ | 3–4 months | PBiEPC: α- and β-globins CD34 + iEPC: γ-globin | From 2 to ~21 |
Soboleva et al. [75] | Lentiviral vector | HPV16 E6/E7 | No | BM | CD34+ |  > 11 months | β- > γ-globin | N.R |